Cargando…

Inhalable antibodies for the treatment of COVID-19

Detalles Bibliográficos
Autores principales:	Yang, Zhenlin, Li, Cheng, Song, Yuanlin, Ying, Tianlei, Wu, Yanling
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9509015/ https://www.ncbi.nlm.nih.gov/pubmed/36186549 http://dx.doi.org/10.1016/j.xinn.2022.100328

Ejemplares similares

Evaluation of vaccine effectiveness against SARS‐CoV‐2 variants by serological epitope profiling
por: Li, Cheng, et al.
Publicado: (2023)

Broad neutralization of SARS-CoV-2 variants by an inhalable bispecific single-domain antibody
por: Li, Cheng, et al.
Publicado: (2022)

A highly stable human single-domain antibody-drug conjugate exhibits superior penetration and treatment of solid tumors
por: Wu, Yanling, et al.
Publicado: (2022)

The prominent role of a CDR1 somatic hypermutation for convergent IGHV3-53/3-66 antibodies in binding to SARS-CoV-2
por: Tian, Xiaolong, et al.
Publicado: (2022)

Insights into biological therapeutic strategies for COVID-19
por: Tian, Xiaolong, et al.
Publicado: (2021)

Standardized inhalation capability assessment: A key to optimal inhaler selection for inhalation therapy
por: Wu, Yixing, et al.
Publicado: (2023)

Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody
por: Tian, Xiaolong, et al.
Publicado: (2020)

Getting hands on a drug for Covid-19: Inhaled and Intranasal Niclosamide
por: Kunzelmann, Karl
Publicado: (2021)

Single-Domain Antibodies as Therapeutics for Respiratory RNA Virus Infections
por: Huang, Keke, et al.
Publicado: (2022)

Single-Domain Antibodies As Therapeutics against Human Viral Diseases
por: Wu, Yanling, et al.
Publicado: (2017)

Potent germline-like monoclonal antibodies: rapid identification of promising candidates for antibody-based antiviral therapy
por: Zhu, Xiaoyi, et al.
Publicado: (2021)

Identification of Human Single-Domain Antibodies against SARS-CoV-2
por: Wu, Yanling, et al.
Publicado: (2020)

Inhaled prostacyclin analogues in COVID-19 associated acute respiratory distress syndrome: scientific rationale
por: Mulia, Eka Prasetya Budi, et al.
Publicado: (2021)

Normal antibody response after COVID-19 during treatment with cladribine
por: Celius, Elisabeth G.
Publicado: (2020)

Antibody-based cancer immunotherapy by targeting regulatory T cells
por: Li, Quanxiao, et al.
Publicado: (2023)

Recent advances in “universal” influenza virus antibodies: the rise of a hidden trimeric interface in hemagglutinin globular head
por: Wang, Yulu, et al.
Publicado: (2020)

Pharmacogenomics of inhalational anesthetic agents
por: Nair, Abhijit S.
Publicado: (2019)

Sterilization plan of the used metered dose inhalers (MDI) to avoid wastage amid COVID-19 pandemic drug shortage
por: Elbeddini, Ali
Publicado: (2020)

Oligonucleotide Delivery to the Lung: Waiting to Inhale
por: Kjems, Jørgen, et al.
Publicado: (2012)

Preparation for the challenge of heavily mutated Omicron variant
por: Song, Yuanlin, et al.
Publicado: (2021)

Antibody responses in mild COVID-19 hospital staff
por: Plebani, Mario
Publicado: (2020)

Antibody tests for diagnosing COVID-19: how relevant are they?
por: Shey, Muki Shehu, et al.
Publicado: (2020)

Discovery of T-Cell Infection and Apoptosis by Middle East Respiratory Syndrome Coronavirus
por: Ying, Tianlei, et al.
Publicado: (2016)

The potential insights of Traditional Chinese Medicine on treatment of COVID-19
por: Tong, Tong, et al.
Publicado: (2020)

Amid COVID-19 drug shortages: proposed plan for reprocessing and reusing salbutamol pressurized metered dose inhalers (pMDIs) for shared use
por: Elbeddini, Ali, et al.
Publicado: (2020)

A non-ACE2 competing human single-domain antibody confers broad neutralization against SARS-CoV-2 and circulating variants
por: Yang, Zhenlin, et al.
Publicado: (2021)

Defining a highly conserved cryptic epitope for antibody recognition of SARS-CoV-2 variants
por: Hao, Aihua, et al.
Publicado: (2023)

Integrative Medicine Demonstrates Advantage in COVID-19 Treatment
por: Cheng, Yung-Chi
Publicado: (2020)

The Use of Respirators to Reduce Inhalation of Airborne Biological Agents
por: Janssen, Larry, et al.
Publicado: (2013)

Standardised neutralising antibody assays are needed for evaluating COVID-19 vaccines
por: Wang, Youchun
Publicado: (2021)

An urgent impetus for action: safe inhalation interventions to reduce COVID-19 transmission and fatality risk among people who smoke crack cocaine in the United Kingdom
por: Harris, Magdalena
Publicado: (2020)

A Promising Intracellular Protein-Degradation Strategy: TRIMbody-Away Technique Based on Nanobody Fragment
por: Chen, Gang, et al.
Publicado: (2021)

In-Depth Analysis of Human Neonatal and Adult IgM Antibody Repertoires
por: Hong, Binbin, et al.
Publicado: (2018)

The use of inhaled corticosteroid in preschool wheezers: what's the point today?
por: Tenero, Laura, et al.
Publicado: (2009)

What is the role of surfactant and inhaled nitric oxide in lung transplantation?
por: Strüber, Martin
Publicado: (2002)

Therapeutic potential of inhalable medications to combat coronavirus disease-2019
por: Parvathaneni, Vineela, et al.
Publicado: (2020)

Commentary: Inhale, exhale - Fighting the invisible enemy with every breath!
por: Das, Anthony Vipin
Publicado: (2021)

Inhaled aptamer therapy: A hopeful therapy for lung disease
por: Martin, M. Elena
Publicado: (2023)

Neutralising antibodies and virus isolation: The keys to control covert COVID-19 spread?
por: Morand, Grégoire B.
Publicado: (2021)

Using SARS-CoV-2 Antibody Testing in COVID-19 Research
por: Amraotkar, Alok R., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_e1grl8io5na1iusurmjinkjipe